The antibody is a dye conjugate which will be used in Phase I and Phase II clinical trials.
Spectros CEO David Benaron said the collaboration with GBI on the conjugation of a fluorescent dye and a monoclonal antibody, the company intends to identify and minimize the residual tumor.
"We look forward to clinical trials with this agent, ProstaFluor, beginning next year," Benaron added.
Goodwin Biotechnology is a cGMP contract manufacturer of monoclonal antibodies, recombinant proteins and vaccines, which specializes in cell line development, process development and GMP manufacturing of recombinant proteins.